Drug Profile
BAY 157496
Latest Information Update: 09 Jul 2002
Price :
$50
*
At a glance
- Originator Bayer
- Class Antiasthmatics
- Mechanism of Action Metalloprotease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 15 Mar 2000 New profile
- 15 Mar 2000 Phase-I clinical trials for Asthma (Unknown route)
- 15 Mar 2000 Phase-I clinical trials for Chronic obstructive pulmonary disease (Unknown route)